Growth Metrics

Pacira BioSciences (PCRX) Net Cash Flow (2016 - 2025)

Pacira BioSciences has reported Net Cash Flow over the past 16 years, most recently at $11.4 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $11.4 million for Q4 2025, down 63.1% from a year ago — trailing twelve months through Dec 2025 was -$118.2 million (down 195.69% YoY), and the annual figure for FY2025 was -$118.2 million, down 195.69%.
  • Net Cash Flow for Q4 2025 was $11.4 million at Pacira BioSciences, up from -$153.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for PCRX hit a ceiling of $451.5 million in Q4 2021 and a floor of -$358.8 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was $11.8 million (2023), compared with a mean of $2.9 million.
  • Biggest five-year swings in Net Cash Flow: soared 1885.67% in 2021 and later crashed 13965.07% in 2025.
  • Pacira BioSciences' Net Cash Flow stood at $451.5 million in 2021, then tumbled by 101.17% to -$5.3 million in 2022, then soared by 1125.15% to $54.2 million in 2023, then plummeted by 43.13% to $30.8 million in 2024, then plummeted by 63.1% to $11.4 million in 2025.
  • The last three reported values for Net Cash Flow were $11.4 million (Q4 2025), -$153.0 million (Q3 2025), and $16.7 million (Q2 2025) per Business Quant data.